The Fosun-backed ophthalmology equipment provider raised cash that will go to research, recruitment and commercialisation activities.

VisionX, a China-based ophthalmology medical device developer backed by conglomerate Fosun, has secured over $100m in series B funding, DealStreetAsia reported on Friday.

New investors Temasek and Lake Bleu Capital participated in the round alongside returning backers Sequoia Capital China, 3H Health Investment, Sherpa Healthcare Partners and Highlight Capital.

Founded in 2018, VisionX provides medical equipment to treat eyesight problems such as myopia, ocular surface disease and other corrections and diagnostics.

The company also sells more consumer-focused products like contact…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Fernando Moncada Rivera

Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
Email LinkedIn